Reversible cardiomyopathy associated with sunitinib and sorafenib

N Engl J Med. 2011 Oct 27;365(17):1649-50. doi: 10.1056/NEJMc1108849.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Benzenesulfonates / adverse effects*
  • Cardiomyopathies / chemically induced*
  • Female
  • Humans
  • Indoles / adverse effects*
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyridines / adverse effects*
  • Pyrroles / adverse effects*
  • Sorafenib
  • Sunitinib
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Sorafenib
  • Protein-Tyrosine Kinases
  • Sunitinib